Tuesday, May 28, 2024
HomeHealth ConditionsDiabetesHow does metformin benefit those with type 1 diabetes and heart disease?

How does metformin benefit those with type 1 diabetes and heart disease?

A recent study, published in the International Journal of Molecular Sciences, investigated the cardioprotective effects of metformin in type 1 diabetes and heart disease.

Studies have shown that patients with diabetes mellitus have a two to four-fold higher risk of developing cardiovascular disease (CVD). Diabetes mellitus is a chronic condition characterized by elevated sugar levels in the blood. Diabetes can be classified into three distinct types: type 1 diabetes mellitus, type 2 diabetes mellitus, and gestational diabetes.

Metformin has shown to have protective effects on blood vessels

Type 1 diabetes, also called juvenile-onset diabetes, occurs when the body is unable to effectively produce insulin. Insulin is a hormone that plays a vital role in sugar balance. In contrast, while patients with type 2 diabetes have adequate insulin levels, the hormone cannot effectively carry out its function due to insulin resistance.

Patients with type 1 diabetes are often treated with insulin therapy, whereas metformin is the drug of choice in type 2 diabetes. Metformin has been shown to have anti-hyperglycemic and lipid-lowering effects, as well as vasculoprotective properties. However, the exact mechanism through which metformin acts is poorly understood and warrants further investigation.

In a recent study called MERIT, published in the International Journal of Molecular Sciences, Ahmed and colleagues investigated the protective role of metformin in type 1 diabetes. They studied its effect on four microRNAs.

What are microRNAs?

MicroRNAs (miRs) are small, single-stranded, non-coding RNA that silence genes by increasing messenger RNA degradation or preventing their translation into functional proteins. The authors focused primarily on miR-222, miR-195, miR-21a, and miR-126 because these have been significantly associated with CVD in the past.

For the study, individuals with type 1 diabetes were divided into two groups. In the treatment group, the patients were treated with metformin. In the standard group, the patients were treated with standard insulin. Researchers also included 23 age and gender-matched healthy participants without diabetes and CVD.

Patients had lower levels of miRs after metformin treatment

In summary, the MERIT study found that individuals with type 1 diabetes with good diabetic control and no CVD had significantly higher levels of plasma miRs at the start of the study. Following eight weeks of metformin, however, patients had significantly lower levels of miR-195, miR-21a, and miR-222. No change was observed in miR-126 levels with metformin treatment.

All four of the miRs studied have been previously implicated in vascular health. More precisely, previous studies have shown that miR-21a levels are associated with vascular damage and other negative health outcomes in patients with diabetes. Another study found that reduced plasma miR-222 levels were associated with reduced circulating endothelial cell levels, a marker of endothelial injury.

In conclusion, these findings collectively suggest that the improved cardioprotective effect of metformin are mediated, in part, by its effects on reducing anti-angiogenic miRs and improving vascular function in diabetic patients.

Written by Haisam Shah, BSc

Reference: Ahmed, F., Bakhashab, S., Bastaman, I., Crossland, R., Glanville, M., & Weaver, J. (2018). Anti-Angiogenic miR-222, miR-195, and miR-21a Plasma Levels in T1DM Are Improved by Metformin Therapy, Thus Elucidating Its Cardioprotective Effect: The MERIT Study. International journal of molecular sciences19(10), 3242.

Haisam Shah BSc
Haisam Shah BSc
Haisam is a first-year Masters student in the Department of Physiology at the University of Toronto. His research involves understanding the role of cardiac fibroblasts in the progressive development of cardiac fibrosis following a myocardial infarction. He graduated from McGill University with a Bachelors of Science – Honors in Pharmacology, where he had the opportunity of investigating potential combination therapies for Glioblastoma Multiforme.


Please enter your comment!
Please enter your name here

Latest News and Articles


Stay Connected

Article of the month

Recognizing HIE: A Call for Advocacy

Have you heard of HIE? It’s the second leading cause of infant mortality and lifelong disability worldwide. 2-3 per 1,000 live births in high-income...

Joke Of The Day – May 28

A medical student was visiting his elderly grandfather and was asking him about the new medication that he was currently taking. "So, I understand that...


error: Content is read-only and copy-protected.